Perindopril

Perindopril
(IUPAC) ime
	(2S,3aS,7aS)-1-[(2S)-2- {[(2S)-1-etoksi-1-oksopentan-2-il]amino}propanoil]-oktahidro-1H-indol-2-karboksilna kiselina
Klinički podaci
Robne marke	Coversyl, Coversum, Preterax, Aceon
AHFS/Drugs.com	Monografija
MedlinePlus	a602017
Identifikatori
CAS broj	82834-16-0
ATC kod	C09AA04 ; C09BA04 (sa diureticima); C09BB04 (sa amlodipinom)
PubChem	107807
DrugBank	DB00790
ChemSpider	96956
UNII	1964X464OJ
KEGG	D03753
ChEBI	CHEBI:8024
ChEMBL	CHEMBL1581
Hemijski podaci
Formula	C19H32N2O5
Mol. masa	368,468 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1 ; Key: IPVQLZZIHOAWMC-QXKUPLGCSA-N
Farmakokinetički podaci
Bioraspoloživost	24%
Vezivanje za proteine plazme	20%
Metabolizam	Renal
Poluvreme eliminacije	1–17 sati za perindoprilat (aktivni metabolit)
Farmakoinformacioni podaci
Trudnoća	D(US)
Pravni status	℞-only (SAD)
Način primene	Oralno

Perindopril je dugotrajni ACE inhibitor. On se koristi za tretman visokog krvnog pritiska, zatajenja srca i koronarne arterijske bolesti^[6] u obliku perindopril arginina (Coversyl, Coversum) ili perindopril erbumina (Aceon). Ova dva preparata su terapeutski ekvivalentna.^[7]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Royal Australian College of General Practitioners. „Consumer Medicine Information, GenRx Perindopril”. Clinical Resources, Medicine information for health professionals. Arhivirano iz originala na datum 2007-09-01. Pristupljeno 2014-04-05.
↑ Australian Government Department of Health and Ageing (2008). „PBS For Health Professionals”. Pharmaceutical Benefits Scheme. Arhivirano iz originala na datum 2008-10-30. Pristupljeno 4. 9. 2008.

Reference

Bounhoure JP, Bottineau G, Lechat P, et al.. "Value of perindopril in the treatment of chronic congestive heart failure: multicentre double-blind placebo-controlled study." Clin Exp Hypertens. 1989;A11(suppl 2):575-586.
Lechat P, Granham SP, Desche P, et al.. "Efficacy and acceptability of perindopril in mild-to-moderate chronic congestive heart failure." Am Heart J. 1993;126:798-806.
Morgan T and Anderson A; "Clinical efficacy of perindopril in hypertension." Clin Exp Pharmacol Physiol. 1992;19:61-65.
Myers MG; (on behalf of the perindopril multicentre dose-response study group) "A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24h after dosing." Can J Cardiol. 1996;12:1191-1196.
"The European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study)." The Lancet 2003;362:782-788.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Official homepage Arhivirano 2014-01-04 na Wayback Machine-u

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Royal Australian College of General Practitioners. „Consumer Medicine Information, GenRx Perindopril”. Clinical Resources, Medicine information for health professionals. Arhivirano iz originala na datum 2007-09-01. Pristupljeno 2014-04-05.

[7] Australian Government Department of Health and Ageing (2008). „PBS For Health Professionals”. Pharmaceutical Benefits Scheme. Arhivirano iz originala na datum 2008-10-30. Pristupljeno 4. 9. 2008.

[1]

[2]

[3]

[4]

[5]

[6]

[7]